Back to News
Market Impact: 0.25
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
Avalyn reported results supporting its strategy of delivering established antifibrotic medicines directly to the lungs. The approach is intended to maximize local drug exposure while reducing systemic exposure and improving tolerability, providing a positive validation of its inhaled-treatment platform.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AVLN0.72
More News
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Asian Markets Tally Losses From Worsening Global Rout
- Magnificent 7 loses $1 trillion. The most eye-popping stats from Thursday's tech stock plunge
- Wall Street’s best post-midterm rally in 44 years lasted just one day—then $3 trillion vanished as chip stocks plunged over AI fears
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction